Results 11 to 20 of about 365,960 (349)
Degludec insulin: A novel basal insulin
Indian Journal of Endocrinology and Metabolism, 2011 This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra +3 more
doaj +3 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Basal insulin have been developed over the years. In recent times newer analogues have been added to the armanentarium for diabetes therapy.
S V Madhu, M Velmurugan
doaj +3 more sources
Cardiovascular effects of basal insulins
Drug, Healthcare and Patient Safety, 2015 Edoardo Mannucci,1 Stefano Giannini,2 Ilaria Dicembrini1 1Diabetes Agency, Careggi Teaching Hospital, Florence, 2Section of Endocrinology, Department of Biomedical Clinical and Experimental Sciences, University of Florence and Careggi University Hospital,
Mannucci E, Giannini S, Dicembrini I
doaj +5 more sources
基于多中心前瞻性真实世界数据的基础胰岛素和预混合胰岛素对2型糖尿病患者血糖控制的影响研究
Journal of Diabetes, 2022 Background To investigate the different efficacies of glycemic control between basal and premixed insulin in participants with type 2 diabetes (T2DM) when non‐insulin medications fail to reach treatment targets.
Ying Peng +15 more
doaj +1 more source
Frontiers in Endocrinology, 2021 Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which targets post-prandial glucose. This expert panel aimed to provide a
Tevfik Demir +5 more
doaj +1 more source
Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review [PDF]
Diabetes & Metabolism Journal, 2021 Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT)
Hwi Seung Kim +4 more
doaj +1 more source
Concentrated insulins: the new basal insulins
Therapeutics and Clinical Risk Management, 2016 Insulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also
Davis, Stephen +2 more
openaire +6 more sources
Basal insulin titration by the app. [PDF]
Lancet Reg Health Eur, 2023 Vangoitsenhoven R, Van der Schueren B.
europepmc +3 more sources
Insulin glargine: a new basal insulin analogue [PDF]
QJM, 2002 Currently, the therapeutic challenges in the treatment of both type 1 and 2 diabetes mellitus (DM) are the maintenance of near‐normal glycaemia, to prevent long‐term complications,1,,2 and the avoidance of episodes of hypoglycaemia. For many people with DM, intensive insulin therapy means multiple insulin injections and frequent blood sampling, at the ...
N, Younis, H, Soran, D, Bowen-Jones
openaire +2 more sources
The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]
, 2018 Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group +47 more
core +1 more source